Tianhong Li, M.D., Ph.D.
Tianhong “Tina” Li is a Professor of Clinical Medicine and thoracic medical oncologist in the Experimental Therapeutics Program at the UC Davis Comprehensive Cancer Center and VA Northern California Health Care System (VANCHCS). Her career goal is to translate innovative treatment strategies and technology advances into direct patient care through early phase clinical trials. Her current translational research focuses on understanding the primary and acquired resistance mechanisms of cancer therapy and improving tissue and blood-based molecular and immune biomarkers for precision lung cancer therapy. She has served as Principal Investigator in many investigator-initiated, multicenter clinical trials and industrial supported phase I trials. She currently leads the Phase I Disease Team at UCD. She received the recognition of "Best Doctors in Sacramento" from Sacramento Magazine in 2020 and 2022.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AbbVieTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AstellasTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AstraZenecaTopic:biomarker researchDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Chugai PharmaTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Duality BiologicsTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Genentech/LaRocheTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Jounce TherapeuticsTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:LabyRx Immuno-OncologyTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:MerckTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:OncoC4/BioNTechTopic:clinical trialDate added:04/26/2024Date updated:04/26/2024